Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H30N8OS |
| Molecular Weight | 490.624 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C[C@@H](NC(=O)N1CC2=C(NN=C2NC3=C4SC=CC4=NC(C)=N3)C1(C)C)C5=CC=CC=C5
InChI
InChIKey=AYCPARAPKDAOEN-LJQANCHMSA-N
InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1
| Molecular Formula | C25H30N8OS |
| Molecular Weight | 490.624 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24366569Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439741 | https://www.ncbi.nlm.nih.gov/pubmed/23543898 | https://www.ncbi.nlm.nih.gov/pubmed/24432870
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24366569
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439741 | https://www.ncbi.nlm.nih.gov/pubmed/23543898 | https://www.ncbi.nlm.nih.gov/pubmed/24432870
PF-3758309 was developed as an ATP-competitive inhibitor of PAK4. In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM). PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model. PF-3758309 is antiproliferative and induces apoptosis in an HCT116 tumor model.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439741
Curator's Comment: # Pfizer, Inc
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4482 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24432870 |
36.0 nM [Ki] | ||
Target ID: CHEMBL4600 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24432870 |
36.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| p21-activated kinase 1 activity is required for histone H3 Ser10 phosphorylation and chromatin condensation in mouse oocyte meiosis. | 2017-07 |
|
| Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. | 2016-09-20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23543898
Five- to six-week-old female athymic nude mice bearing colorectal cancer xenograft were treated for 14 days with either vehicle control (0.5% methylcellulose), or PF-3758309 (25 mg/kg) twice daily by oral gavage.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23543898
To evaluate the sensitivity of colorectal cancer (CRC) cell lines to PF-3758309, a panel of 27 CRC cell lines were exposed to increasing concentrations and assessed for proliferation using the SRB assay. Treatment of RKO, COLO205, HTC116, SW620, SW480, SW48, LS123, SW403, LOVO, LS180, SKC01, COLO201, LS513 and LS174T cell lines with PF-3758309 (0.1nM-1mkM) for 72 h leads to inhibition of cell proliferation (IC50< 0.0125mkM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:58:16 GMT 2025
by
admin
on
Mon Mar 31 20:58:16 GMT 2025
|
| Record UNII |
PK459EA5I2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB11775
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY | |||
|
C84841
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL3128043
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY | |||
|
25227462
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY | |||
|
DTXSID70649389
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY | |||
|
PK459EA5I2
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY | |||
|
300000041320
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY | |||
|
898044-15-0
Created by
admin on Mon Mar 31 20:58:16 GMT 2025 , Edited by admin on Mon Mar 31 20:58:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
F-3758309 is antiproliferative and induces apoptosis in a HCT116 tumor model.
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |